BREAST CANCER

NEOADJUVANT THERAPY

HR-positive
HER2-negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

IRB# 21243
Neoadjuvant Abemaciclib and Niraparib (PANNTHR)

IRB# 22191
Keynote-756: Pembrolizumab/Placebo in combo with neoadjuvant chemotherapy & Adjuvant Endocrine Therapy

HER2-positive

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

Triple Negative

IRB# 6256
ISPY-2: Neoadjuvant and Personalized Adaptive Novel Agents

http://www.ohsu.edu/research/rda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold
HR-positive HER2-negative

**IRB#22395**

**DARE:** DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III

HER2-positive

No trials currently available

Triple Negative

No trials currently available

---

http://www.ohsu.edu/research/rda/so/knight.php
BREAST CANCER

METASTATIC THERAPY

HR-positive
HER2-negative

ENDOCRINE

Physician's Choice

CHEMO

>2L

IRB 23756
DESTINY
Breast08:
Phase 1b
Study of T-DXd
Combinations in HER2-
low a/mBC

IRB 23761
postMONARCH:
Abemaciclib/placebo +
Fulvestrant

IRB#22225
SERENA-4:
AZD9833 with palbociclib vs.
anastrozole with palbociclib

IRB 23755
OP-1250-001:
A Dose
Escalation/Expansion study of OP-1250

IRB 23761
postMONARCH:
Abemaciclib/placebo +
Fulvestrant

IRB#22225
OP-1250-001:
A Dose
Escalation/Expansion study of OP-1250

IRB 23761
postMONARCH:
Abemaciclib/placebo +
Fulvestrant

IRB#22225
SERENA-4:
AZD9833 with palbociclib vs.
anastrozole with palbociclib

IRB 23755
OP-1250-001:
A Dose
Escalation/Expansion study of OP-1250

IRB 23755
OP-1250-001:
A Dose
Escalation/Expansion study of OP-1250

IRB#21441
EA1183:
FDG-PET/CT

IRB#21441
EA1183:
FDG-PET/CT

IRB#23524
TROPION
Breast01:
DATO-DXd
vs. Chemo

IRB#23524
TROPION
Breast01:
DATO-DXd
vs. Chemo

IRB#23524
TROPION
Breast01:
DATO-DXd
vs. Chemo

IRB#23524
TROPION
Breast01:
DATO-DXd
vs. Chemo

IRB#22225
SERENA-4:
AZD9833 with palbociclib vs.
anastrozole with palbociclib

IRB#22225
SERENA-4:
AZD9833 with palbociclib vs.
anastrozole with palbociclib

IRB#22225
SERENA-4:
AZD9833 with palbociclib vs.
anastrozole with palbociclib

IRB#22225
SERENA-4:
AZD9833 with palbociclib vs.
anastrozole with palbociclib

http://www.ohsu.edu/research/rda/so/knight.php

08 Feb 2022
BREAST CANCER

METASTATIC THERAPY

1L
- IRB#21441 EA1183: FDG-PET/CT
- IRB#19078 S1501: Carvediol in Preventing Cardiac Toxicity

2L
- IRB#21441 EA1183: FDG-PET/CT
- IRB#19078 S1501: Carvediol in Preventing Cardiac Toxicity

>2L
- IRB#19078 S1501: Carvediol in Preventing Cardiac Toxicity

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php
**BREAST CANCER**

**METASTATIC THERAPY**

**Triple Negative**

1L

**IRB#18504**

**AMTEC**: Olaparib + Durvalumab

2L

**IRB#18504**

**AMTEC**: Olaparib + Durvalumab

**IRB 22765 DESTINY Breast08**: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC

>2L

**IRB#18504**

**AMTEC**: Olaparib + Durvalumab

**IRB 22765 DESTINY Breast08**: Phase 1b Study of T-DXd Combinations in HER2-low a/mBC

http://www.ohsu.edu/research/rda/so/knight.php

---

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold
<table>
<thead>
<tr>
<th>Trial ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB#15588</td>
<td>• Heavily Pre-treated</td>
</tr>
<tr>
<td>(SMMART-PRIME)</td>
<td>• HR+HER2-; HER2+; TNBC</td>
</tr>
<tr>
<td>IRB#20679</td>
<td>• HR+HER2-; HER2+; TNBC</td>
</tr>
<tr>
<td>(SMMART-ACT)</td>
<td>• Pre-screen (molecular target)</td>
</tr>
<tr>
<td>IRB#19904</td>
<td>• Heavily Pre-treated</td>
</tr>
<tr>
<td>NEO-RAY (Nuc Med)</td>
<td>• Pre-screen required</td>
</tr>
<tr>
<td>IRB# 19992</td>
<td>• Pre-screen (molecular target)</td>
</tr>
<tr>
<td>EAY131 (MATCH)</td>
<td></td>
</tr>
<tr>
<td>IRB#18084</td>
<td>• Pre-screen (rare molecular target)</td>
</tr>
<tr>
<td>S1609 (DART)</td>
<td></td>
</tr>
<tr>
<td>IRB#19489</td>
<td>• Targeting Metastatic Breast Cancer and Breast Cancer Stem Cells with Lutathera</td>
</tr>
<tr>
<td>(Lutathera IIT)</td>
<td></td>
</tr>
<tr>
<td>IRB#16676</td>
<td>• Advanced solid tumor with oncognenic RET fusion (expected to close soon)</td>
</tr>
<tr>
<td>BLU-667 (Phase 1)</td>
<td></td>
</tr>
<tr>
<td>IRB#18164</td>
<td>• RET fusion-positive</td>
</tr>
<tr>
<td>Loxo RET (Phase 1)</td>
<td></td>
</tr>
<tr>
<td>IRB#</td>
<td>Trial Details</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>21349</td>
<td><strong>TNBC</strong>: Previously treated (cytotoxic or targeted anticancer agents) in the metastatic setting.</td>
</tr>
<tr>
<td></td>
<td>MORAB-202 (Phase 1)</td>
</tr>
<tr>
<td>21766</td>
<td><strong>Patients must have progressed on at least two lines of approved therapy for their histological subtype</strong></td>
</tr>
<tr>
<td></td>
<td>GEN001 (Phase 1)</td>
</tr>
<tr>
<td>21508</td>
<td><strong>TNBC</strong> with no alternative effective standard therapy</td>
</tr>
<tr>
<td></td>
<td>ORIC-101 (Phase 1)</td>
</tr>
<tr>
<td>21548</td>
<td><strong>TNBC</strong> relapsed/refractory to at least one line of systemic chemotherapy in the metastatic setting or intolerant of existing therapy(ies).</td>
</tr>
<tr>
<td></td>
<td>AMG 650 (Phase 1)</td>
</tr>
<tr>
<td>21819</td>
<td><strong>Phase 1B</strong>: documented activating gene mutations in BRAF (BRAF V600 mutation or activating atypical non-V600 aberrations), KRAS, NRAS, or HRAS</td>
</tr>
<tr>
<td></td>
<td>ASTX029 (Phase 1)</td>
</tr>
</tbody>
</table>

To inquire about Phase 1 trial open slots please contact stadnik@ohsu.edu.

http://www.ohsu.edu/research/rda/so/knight.php